Lion Point Capital’s bluebird bio BLUE Stock Holding History

Lion Point Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-78,912	Closed	-$385K	–	20
2025 Q1	$385K	Hold	78,912	–	–	2.46%	17
2024 Q4	$658K	Sell	78,912 -1	-0%	-$9	3.45%	15
2024 Q3	$820K	Buy	78,913 +45,000	+133%	+$748K	1.83%	15
2024 Q2	$668K	Sell	33,913 -8,500	-20%	-$170K	1.22%	18
2024 Q1	$1.09M	Buy	42,413 +15,850	+60%	+$406K	0.61%	15
2023 Q4	$733K	Hold	26,563	–	–	0.37%	17
2023 Q3	$1.62M	Hold	26,563	–	–	0.72%	12
2023 Q2	$1.75M	Buy	+26,563	New	+$1.94M	0.79%	12

Other funds holding BLUE

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Lion Point Capital's BLUE Position: Q2 2025 in Review

Lion Point Capital sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 78,912 shares — an estimated $385K sold.

Lion Point Capital first reported a position in BLUE in Q2 2023 and held it in 8 quarters. The position peaked at $1.75M in Q2 2023. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

Lion Point Capital reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
Lion Point Capital sold 78,912 bluebird bio shares in Q2 2025, an estimated $385K.
Lion Point Capital first reported a position in bluebird bio in Q2 2023 and held it in 8 quarters.
Lion Point Capital's bluebird bio position peaked at $1.75M in Q2 2023.
3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on Lion Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.